From: Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
Disease | Target | Name | Antibody format |
---|---|---|---|
AML | CD123-CD3 | MGD006 | DART |
 |  | XmAb14045 | XmAb |
 | CD33-CD3 | AMG 330 | BiTE |
 |  | AMV 564 | TandAb |
 | FLT3-CD3 | 7370 | BiTE |
 | CLEC12A-CD3 | MCLA-117 | Biclonics |
 | WT1-CD3 | ESK1-BiTE | BiTE |
ALL | CD19-CD3 | Blinatumomab | BiTE |
 |  | AFM11 | TandAb |
MM | BCMA-CD3 | AMG420 | BiTE |
 |  | AMG701 | BiTE-Fc |
 | GPRC5D-CD3 | Talquetamab | DuoBody |
 | CD38-CD3 | AMG424 | XmAb |
 |  | Bi38-3 | BiTE |
 | FCRL5-CD3 | anti-FcRH5/CD3 TDB | Knobs-into-holes |
NHL | CD19-CD3 | Blinatumomab | BiTE |
 | CD20-CD3 | REGN1979 | Veloci-Bi platform |
 |  | Mosunetuzumab | Knobs-into-holes |
 |  | RG6026 | 2:1 CrossMab |
MDS | CD33-CD3 | AMV564 | TandAb |
 | CD123-CD3 | MGD006 | DART |